Filing Flows › AtriCure (ATRC) › R&D spending
AtriCure (ATRC) R&D spending by quarter
AtriCure's R&D spending was $32.1M in Q3 2026 (third quarter 2026), +22% from Q2 2026. Over the last 7 quarters it ranged from $22.5M (Q1 2025) to $32.1M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $32.1M | +22% | +40% |
| Q2 2026 | $26.4M | +9% | -10% |
| Q1 2026 | $24.2M | -1% | +8% |
| Q4 2025 | $24.5M | +7% | — |
| Q3 2025 | $22.9M | -22% | — |
| Q2 2025 | $29.3M | +30% | — |
| Q1 2025 | $22.5M | — | — |
Q3 2026 at a glance
AtriCure, Q3 2026: revenue $154M (+15% year over year), operating margin 2.8%, net earnings $4.1M, operating cash flow $30.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is AtriCure's R&D spending?
AtriCure's R&D spending was $32.1M in Q3 2026 (third quarter 2026), +22% from Q2 2026.
How has AtriCure's R&D spending changed?
Over the last 7 quarters it ranged from $22.5M (Q1 2025) to $32.1M (Q3 2026).